Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | HTR2C | P28335 | 3/20 | 0.49 |
| ▸ | HTR2B | P41595 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13588400 | 0.88 | SIGMAR1 (0.62) | KCNH2DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL19652144 | 0.86 | CHRM2 (0.54) | KCNH2SIGMAR1 | |
| SCHEMBL19652125 | 0.85 | CCR5 (0.51) | KCNH2DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL19658472 | 0.85 | KCNH2 (0.53) | KCNH2DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL19658765 | 0.83 | OPRM1 (0.56) | KCNH2DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL19652161 | 0.82 | ACHE (0.50) | KCNH2L3MBTL1HRH1CACNA1I | |
| SCHEMBL19652090 | 0.81 | SIGMAR1 (0.54) | KCNH2DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL12074554 | 0.78 | ALDH1A1 (0.56) | KCNH2L3MBTL1HRH1 | |
| SCHEMBL19652127 | 0.77 | MLNR (0.52) | KCNH2DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL5413141 | 0.76 | KCNH2 (0.67) | KCNH2DRD2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | KCNH2 3447/4885DRD2 2016/4885HTR2A 3753/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | KCNH2 3447/4885DRD2 2016/4885HTR2A 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.